Media coverage
14
Media coverage
Title Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021 Media name/outlet Morningstar.com Country/Territory United States Date 12/05/21 URL https://www.morningstar.com/news/pr-newswire/20210512sf74899/protagonist-therapeutics-announces-presentation-of-updated-results-from-phase-2-study-of-rusfertide-in-polycythemia-vera-selected-for-oral-presentation-at-eha-2021 Persons Marina Kremyanskaya Title Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021; Updated Phase 2 analysis to be presented by Dr. Marina Kremyanskaya, Icahn School of Medi Media name/outlet PR Newswire Country/Territory United States Date 12/05/21 Persons Marina Kremyanskaya Title Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021 Media name/outlet India Pharma News Country/Territory India Date 12/05/21 Persons Marina Kremyanskaya Title Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021 Media name/outlet Finanzen.net Country/Territory Germany Date 12/05/21 URL https://www.finanzen.net/nachricht/aktien/protagonist-therapeutics-announces-presentation-of-updated-results-from-phase-2-study-of-rusfertide-in-polycythemia-vera-selected-for-oral-presentation-at-eha-2021-10129990 Persons Marina Kremyanskaya Title Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera,.. Media name/outlet ADVFN UK Country/Territory United Kingdom Date 12/05/21 URL https://uk.advfn.com/stock-market/NASDAQ/PTGX/share-news/Protagonist-Therapeutics-Announces-Presentation-of/85089475 Persons Marina Kremyanskaya Title Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021 Media name/outlet Finanzen.ch Country/Territory Switzerland Date 12/05/21 URL https://www.finanzen.ch/nachrichten/aktien/protagonist-therapeutics-announces-presentation-of-updated-results-from-phase-2-study-of-rusfertide-in-polycythemia-vera-selected-for-oral-presentation-at-eha-2021-1030422003 Persons Marina Kremyanskaya Title Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021 Media name/outlet Yahoo! Finance Country/Territory United States Date 12/05/21 URL https://finance.yahoo.com/news/protagonist-therapeutics-announces-presentation-updated-151400829.html Persons Marina Kremyanskaya Title Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021 Media name/outlet TickerTech.com Country/Territory United States Date 12/05/21 URL www.tickertech.com/cgi/?a=news&ticker=a&w=&story=202105202105121114PR_NEWS_USPR_____SF74899 Persons Marina Kremyanskaya Title Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021 Media name/outlet Yahoo! News Country/Territory United States Date 12/05/21 URL https://www.yahoo.com/now/protagonist-therapeutics-announces-presentation-updated-151400829.html Persons Marina Kremyanskaya Title Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021 Media name/outlet ProfitQuotes.com Country/Territory United States Date 12/05/21 URL www.profitquotes.com/cgi/?a=news&ticker=a&w=&story=202105202105121114PR_NEWS_USPR_____SF74899 Persons Marina Kremyanskaya Title Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021 Media name/outlet TD Ameritrade Country/Territory United States Date 12/05/21 URL https://research.tdameritrade.com/grid/public/markets/news/story.asp?fromPage=results&docKey=100-132p2524 Persons Marina Kremyanskaya Title Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Sel... Media name/outlet ADVFN US Country/Territory United States Date 12/05/21 URL https://www.advfn.com/p.php?pid=nmona&article=85089475 Persons Marina Kremyanskaya Title Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021 Media name/outlet Stockwatch Country/Territory Canada Date 12/05/21 URL www.stockwatch.com/News/Item/U-prSF74899-U!PTGX-20210512/U/PTGX Persons Marina Kremyanskaya Title Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021 Media name/outlet WFMZ-TV Online Country/Territory United States Date 12/05/21 URL https://www.wfmz.com/news/pr_newswire/pr_newswire_health/protagonist-therapeutics-announces-presentation-of-updated-results-from-phase-2-study-of-rusfertide-in-polycythemia/article_93d1b62a-dae3-5e8f-8380-5f7cec6e16e6.html Persons Marina Kremyanskaya